STERIS plc's Stock Analysis

STERIS Reports Revenue Growth and New Share Repurchase Program

STERIS plc announced its financial results for the fourth quarter and full year of fiscal 2026, reporting a 9% increase in revenue from continuing operations, totaling $5.9 billion. The diluted earnings per share (EPS) from continuing operations rose to $7.93, while adjusted EPS increased to $10.17. In the fourth quarter alone, revenue grew 7% to $1.6 billion, with notable performance in the Healthcare segment, which saw a 7% rise in revenue, driven by improved service and consumable sales.

The Company generated $1.34 billion in net cash from operations and reported free cash flow of $982.9 million for fiscal 2026. STERIS's Board of Directors has approved a new share repurchase program allowing for the buyback of up to $1 billion of the Company's ordinary shares. The Company anticipates a revenue increase of 7-8% for fiscal 2027 and plans to invest approximately $375 million in capital expenditures, including a new manufacturing facility in Ohio.

May 11, 2026 16:34:04

STERIS Appoints New Director Following Board Changes

Richard C. Breeden announced he will not seek reelection to STERIS plc's Board of Directors at the 2026 Annual General Meeting. His retirement is not due to any disagreements with the Company. The Board has increased its size from nine to ten members with the appointment of Pierre Boulud, the current CEO of bioMérieux, effective May 5, 2026. Boulud brings extensive experience in biotechnology and pharmaceuticals, having held various leadership roles in his previous positions.

Pierre Boulud will receive a prorated fee of $76,989 for his service on the Board, payable in restricted stock units. His appointment was publicly announced on May 7, 2026. STERIS focuses on providing healthcare and life sciences products and services aimed at infection prevention and improving patient care. The Company continues to engage with its stakeholders to communicate its operational and strategic developments.

May 07, 2026 16:35:55

STERIS Extends Advisor Role for Former CFO with Salary Cut

STERIS plc has amended the Transition Agreement with former Chief Financial Officer Michael J. Tokich, extending his role as a senior financial advisor on a part-time basis from April 1, 2026, to March 31, 2027. During this period, Tokich's annual base salary will be reduced to $60,000, and he will be eligible for a discretionary cash bonus, subject to CEO approval.

Additionally, Tokich will no longer receive benefits from the Company's health and dental plans, life insurance, vacation, disability, or other employee benefit programs. The other terms of the original Agreement will remain in effect throughout the Extended Advisor Period.

Apr 06, 2026 17:02:50

STERIS Reports 9% Revenue Growth for Fiscal Q3 2026

STERIS plc announced its financial results for the third quarter of fiscal 2026, ending December 31, 2025, reporting total revenue from continuing operations of $1.5 billion, a 9% increase compared to $1.4 billion in the same quarter of fiscal 2025. Net income for the quarter was $192.9 million, or $1.96 per diluted share, up from $173.6 million, or $1.75 per diluted share, in the prior year. Adjusted net income was $249.4 million, or $2.53 per diluted share, compared to $229.1 million, or $2.32 per diluted share, in the previous year, reflecting strong performance across various segments despite challenges from tariffs and inflation.

In terms of segment performance, healthcare revenue grew by 9% to $1.1 billion, with notable increases in service, consumable, and capital equipment revenues. The Applied Sterilization Technologies segment reported an 11% revenue increase to $286.6 million, driven by significant growth in capital equipment. Life Sciences revenue also rose by 7% to $145.8 million. The company provided an outlook for fiscal 2026, expecting revenue growth of 8-9% and adjusted earnings per diluted share in the range of $10.15 to $10.30, while noting an anticipated negative impact from tariffs on pre-tax profit.

Feb 04, 2026 16:32:07

STERIS Reports 10% Revenue Growth in Fiscal Q2 2026

STERIS plc announced its financial results for the second quarter of fiscal 2026, reporting a 10% increase in total revenue from continuing operations, reaching $1.5 billion compared to $1.3 billion in the same quarter last year. Net income from continuing operations was $191.9 million, or $1.94 per diluted share, up from $150.2 million, or $1.51 per diluted share in the prior year. The company also experienced organic revenue growth of 9% in constant currency, with notable contributions from its Healthcare segment, which saw a revenue increase of 9% to $1,033.8 million, and a 13% growth in revenue from its Applied Sterilization Technologies segment.

For fiscal 2026, STERIS has raised its outlook, now expecting revenue growth from continuing operations to be between 8-9%, with adjusted earnings per diluted share projected to be in the range of $10.15 to $10.30. The company reported a significant increase in free cash flow for the first half of fiscal 2026, amounting to $527.7 million, driven by growth in earnings and working capital improvements. Despite facing challenges such as tariff costs and inflation, the company continues to enhance its financial performance and operational efficiency.

Nov 05, 2025 16:41:05

STERIS plc Announces Financial Results and Executive Changes

On August 6, 2025, STERIS plc reported a 9% increase in total revenue for the first quarter of fiscal 2026, reaching $1.4 billion. Net income from continuing operations also grew to $177.4 million, or $1.79 per diluted share, compared to $139.8 million, or $1.41 per diluted share, in the same quarter of the previous year. The Healthcare segment saw an 8% revenue increase, while the Applied Sterilization Technologies segment reported a 13% rise. The company expects revenue growth to be between 8-9% for fiscal 2026, influenced by favorable foreign currency rates, although tariffs are projected to negatively impact profits by approximately $45 million.

In leadership changes, Michael J. Tokich resigned as Chief Financial Officer, with his role transitioning to a senior financial advisor until March 2026. Karen Burton will assume the CFO position effective August 18, 2025, with a base salary of $600,000 and a target bonus opportunity of 75% of her salary. The company also announced changes to its Board of Directors, including the election of Louis Shapiro. The annual meeting of shareholders confirmed the appointment of Ernst & Young as the company’s independent registered public accounting firm for the upcoming fiscal year.

Aug 06, 2025 16:39:15

Dr. Richard Steeves to Retire from STERIS Board

Dr. Richard Steeves has announced his retirement from the Board of Directors of STERIS plc, effective July 31, 2025, coinciding with the Company's Annual General Meeting of Shareholders. He will not seek re-election at this meeting, concluding a decade of service on the Board.

The Company confirmed that Dr. Steeves' retirement is not due to any disagreements regarding its strategy, operations, policies, or practices. The Board and the Company expressed their gratitude for his contributions during his tenure.

Jul 03, 2025 16:30:29

Dr. Richard Steeves to Retire from STERIS Board in 2025

Dr. Richard Steeves has announced his retirement from the Board of Directors of STERIS plc, effective July 31, 2025, coinciding with the Company's Annual General Meeting of Shareholders. He will not seek re-election at this meeting. Dr. Steeves' decision is not due to any disagreements regarding the Company’s strategy or operations, and the Company expresses gratitude for his decade of service on the Board.

The announcement of Dr. Steeves' retirement comes as part of a routine transition within the Board. His tenure as a Director has spanned 10 years, and his departure may prompt considerations regarding the future composition of the Board and its potential impact on company governance and direction.

Jul 03, 2025 16:30:29

STERIS Reports Fiscal 2025 Financial Results and Outlook

STERIS plc announced its financial results for the fourth quarter and full year of fiscal 2025, reporting a 6% increase in revenue from continuing operations, totaling $5.5 billion. The diluted earnings per share (EPS) from continuing operations rose to $6.16, while adjusted EPS increased to $9.22. In the fourth quarter alone, revenue from continuing operations reached $1.5 billion, reflecting a 4% increase compared to the same period last year, with a constant currency organic revenue growth of 6%. The company reported net income from continuing operations of $146.5 million for the fourth quarter, down slightly from $152.9 million in the prior year, but adjusted net income increased to $270.3 million from $240.1 million year-over-year.

Looking ahead, STERIS provided an outlook for fiscal 2026, expecting a revenue increase of 6-7% from continuing operations. The company anticipates that adjusted earnings per diluted share will range from $9.90 to $10.15, representing a 7-10% increase compared to the previous fiscal year. The outlook also includes a negative impact from tariffs, estimated to reduce pre-tax profit by approximately $30 million. Free cash flow for fiscal 2026 is projected to be around $770 million, with capital expenditures expected to be approximately $375 million.

May 14, 2025 16:34:06

STERIS Reports $1.4 Billion Revenue in Q3 Fiscal 2025

STERIS plc announced a 6% increase in total revenue from continuing operations for the third quarter of fiscal 2025, reaching $1.4 billion, up from $1.3 billion in the same period last year. The company reported earnings per share (EPS) from continuing operations increased to $1.75, with adjusted EPS rising to $2.32. Healthcare revenue grew by 7%, driven by significant improvements in consumable and service revenue, although capital equipment revenue saw a decline of 5%. The Applied Sterilization Technologies segment also experienced a 10% revenue increase, while the Life Sciences segment reported a 7% decrease in revenue due to a divestiture and declining capital equipment sales. Cash flow from operations for the first nine months of fiscal 2025 was $887.3 million, up from $718.5 million in the previous year, contributing to a free cash flow increase to $588.1 million from $457.0 million last year.

Conversely, STERIS updated its fiscal 2025 outlook, now expecting revenue growth of approximately 6%, a reduction from earlier expectations of 6.5% to 7.5%. This adjustment was primarily attributed to unfavorable currency impacts and lower anticipated capital equipment revenue in the Healthcare segment. The adjusted earnings per diluted share forecast was also slightly lowered to a range of $9.05 to $9.15, reflecting about a ten-cent negative currency impact. Additionally, the Life Sciences segment faced challenges with a 7% revenue decline, largely due to the divestiture of a business unit and decreased capital equipment sales.

Feb 05, 2025 16:33:40